Clinical characteristics and their correlations with CT erosion score. Data are mean (SD) unless indicated otherwise.
| Clinical Features | Pearson r | P | |
|---|---|---|---|
| Age, yrs | 56 (12) | −0.05 | 0.66 |
| Male sex, n (%) | 94 (94) | — | 0.24† |
| Ethnicity, n (%) | — | 0.03† | |
| Pacific | 42 (42) | ||
| Māori | 18 (18) | ||
| Non-Māori, non-Pacific | 40 (40) | ||
| Gout disease duration, yrs | 22 (11) | 0.20 | 0.051 |
| No. subcutaneous tophi | 7.3 (7.1) | 0.62 | < 0.001 |
| Serum urate, mmol/l | 0.38 (0.12) | 0.22 | 0.29 |
| Serum creatinine, μmol/l | 97 (23) | 0.34 | 0.001 |
| RANKL concentration, pmol/l | 0.28 (0.65) | 0.44 | 0.001 |
| OPG concentration, pg/ml | 2214 (1272) | 0.27 | 0.006 |
| Sclerostin concentration, pg/ml | 696 (338) | −0.29 | 0.003 |
| DKK-1 concentration, pg/ml | 3412 (1992) | −0.08 | 0.46 |
| FGF-23 concentration, pg/ml | 7.1 (11.8) | 0.18 | 0.08 |
| P1NP concentration, μg/l | 56.9 (33.3) | 0.16 | 0.12 |
| β-CTX concentration, ng/ml | 0.29 (0.16) | 0.07 | 0.46 |
Pearson r and p refer to correlation with CT erosion score.
↵† P value shown for comparison of erosion scores between groups. CT: computed tomography; RANKL: receptor activator of nuclear factor-κB ligand; OPG: osteoprotegerin; DKK: Dickkopf 1; FGF-23: fibroblast growth factor 23; P1NP: procollagen type-1 N-terminal propeptide; CTX: collagen cross-linked C-telopeptide, type I.